Kiniksa Pharmaceuticals Ltd

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)


· · December 31, · · December 31,
· 2023 · 2022
Assets · ·
Current assets: · · ·
Cash and cash equivalents	$107,954	$122,715
Short-term investments	98,417	67,893
Accounts receivable, net	21,266	12,660
Contract asset	—	7,656
Inventory	31,122	21,599
Prepaid expenses and other current assets	17,538	10,537
Total current assets	276,297	243,060
Property and equipment, net	734	1,658
Operating lease right-of-use assets	11,931	5,385
Other long-term assets	827	5,824
Intangible asset, net	17,250	18,250
Deferred tax assets	219,283	185,495
Total assets	$526,322	$459,672

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$8,246	$7,899
Accrued expenses	44,667	30,112
Deferred revenue	307	—
Operating lease liabilities	2,253	3,301
Other current liabilities	8,193	5,754
Total current liabilities	63,666	47,066
Non-current liabilities:
Non-current deferred revenue	11,954	12,000
Non-current operating lease liabilities	10,005	2,618
Other long-term liabilities	1,858	1,839
Total liabilities	87,483	63,523
Commitments and contingencies (Note 16)
Shareholders’ equity:
Class A common shares, par value of $0.000273235 per share; 35,781,373 shares and 34,750,560 shares issued and outstanding as of December 31, 2023 and 2022, respectively	10	9
Class B common shares, par value of $0.000273235 per share; 1,795,158 shares and 1,813,457 shares issued and outstanding as of December 31, 2023 and 2022, respectively	1	1
Class A1 common shares, $0.000273235 par value; 16,826,468 shares and 17,075,868 issued and outstanding as of December 31, 2023 and 2022, respectively	5	5
Class B1 common shares, $0.000273235 par value; 16,057,618 shares issued and outstanding as of December 31, 2023 and 2022	4	4
Additional paid-in capital	916,763	888,120
Accumulated other comprehensive income	6	44
Accumulated deficit	(477,950)	(492,034)
Total shareholders’ equity	438,839	396,149
Total liabilities and shareholders’ equity	$526,322	$459,672

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.